ASCO 2022 Conference Coverage


 

ASCO 2022 IMMUTACE - A Biomarker-Orientated Phase II, Single-Arm, Open-Label AIO Study of Transarterial Chemoembolization + Nivo Performed for Intermediate-Stage HCC: Updated Efficacy Results

96 views
June 15, 2022
Comments 0
Login to view comments. Click here to Login